Brought to you by 
Purdue in-licenses SpineThera's pain candidate SX600; gets option to acquire company
25 Oct 2018
Executive Summary
Purdue Pharma LP licensed worldwide rights to SpineThera Inc.'s preclinical pain candidate SX600 and the IP surrounding it. Purdue also secured an exclusive option to acquire the company outright.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes M&A Option
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Purdue in-licenses SpineThera's pain candidate SX600; gets option to acquire company
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice